← Leaderboards
Ryan K Shields
University Of Pittsburgh At Pittsburgh
$1,445,715
Attributed
$1,445,715
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $259.3K · FY2015–22$500K$375K$250K$125K$0
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$1,445,715 · 3
By mechanism
K08$857,798 · 1
R21$431,417 · 1
R03$156,500 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Yohei Doi$5,766,320
- Pallavi Ghosh$3,930,342
- Ghady Haidar$895,725
- Joel L Weissfeld$8,317,064
- Fernanda P. Silveira$4,141,926
Others in their field
Top investigators on “Treatment Strategy”
- Judith S. Currier · University Of California Los Angeles$326,447,489
- James Dennis Neaton · Northwestern University$268,647,311
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$261,495,178
- Gregory H Reaman · National Childhood Cancer Foundation$245,370,829
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$224,698,529
- Constance Ann Benson · University Of California, San Diego$222,959,772
Research focus
Treatment StrategySuccessMutantTranslatingResistanceSiteMeasurementMolecularPreventPredispositionLiquid SubstanceRegimenResistance MechanismLaboratoriesClinically RelevantFutureAntimicrobialDoseMutationDrug KineticsFiberEnzymesInfectionPathogen
Grant awards (9)
Use of site-specific pharmacokinetics to optimize antibiotic combinations and prevent the emergence of resistance against CRE$196,667
R21 · FY2022 · AI · contact PI
Use of site-specific pharmacokinetics to optimize antibiotic combinations and prevent the emergence of resistance against CRE$234,750
R21 · FY2021 · AI · contact PI
Characterization and suppression of resistance to new CRE agents$78,250
R03 · FY2020 · AI · contact PI
Caspofungin pharmacokinetics-pharmacodynamics during intra-adbominal candidiasis$181,038
K08 · FY2019 · AI · contact PI
Characterization and suppression of resistance to new CRE agents$78,250
R03 · FY2019 · AI · contact PI
Caspofungin pharmacokinetics-pharmacodynamics during intra-adbominal candidiasis$181,038
K08 · FY2018 · AI · contact PI
Caspofungin pharmacokinetics-pharmacodynamics during intra-adbominal candidiasis$180,438
K08 · FY2017 · AI · contact PI
Caspofungin pharmacokinetics-pharmacodynamics during intra-adbominal candidiasis$157,642
K08 · FY2016 · AI · contact PI
Caspofungin pharmacokinetics-pharmacodynamics during intra-adbominal candidiasis$157,642
K08 · FY2015 · AI · contact PI